Boston, MA, United States of America

Patrick Sutphin

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Auckland Uniservices Limited, Leland Stanford Junior University, Ruga Corporation. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick Sutphin. Retrieved from https://idiyas.com/inventor/patrick-sutphin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Patrick Sutphin: Innovator in Synthetic Lethal Targeting

Introduction

Patrick Sutphin is an accomplished inventor based in Boston, MA (US). He has made significant contributions to the field of biotechnology, particularly in the area of cancer research. His innovative approach focuses on targeting glucose transport mechanisms to inhibit the growth of specific cancer cells.

Latest Patents

Patrick holds 1 patent for his invention titled "Synthetic lethal targeting of glucose transport." This patent provides methods for inhibiting the growth and proliferation of HIF pathway proficient cells by administering GLUT1 inhibitors. This groundbreaking work has the potential to advance therapeutic strategies in cancer treatment.

Career Highlights

Throughout his career, Patrick has worked with notable organizations, including Auckland Uniservices Limited and Leland Stanford Junior University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to significant research initiatives.

Collaborations

Patrick has collaborated with esteemed colleagues such as John Irwin and Denise Chan. These partnerships have enriched his research and expanded the impact of his work in the scientific community.

Conclusion

Patrick Sutphin is a notable inventor whose work in synthetic lethal targeting has the potential to transform cancer treatment. His innovative methods and collaborations highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…